Big pharma often plays “fund, license, kill” - a strategy which requires extreme precision in an industry where missing a competitor or hallucinating a patent number is a never-event.
Andrey Doronichev, CEO, OPTIC | Onyx Live | JPM 2026
Agentic AI makes a big splash in biopharma.
Related
Bernd Mühlenweg, CBO/CFO, Cellbox Solutions | Onyx Live | Cell & Gene Meeting on the Med 2026
More and more cell types cannot be frozen anymore. If you think about organoids, mixed cultures, artificial tissues – all of those require warm chain logistics.
Sarmitha Sathiamoorthy, President & Founder, AspireBio Consulting | Onyx Live | Cell & Gene Meeting on the Med 2026
In a funding-constrained biotech market, most early-stage teams still try to reinvent the AAV and advanced-therapy CMC playbooks the industry has already solved a dozen times over.
Alberto Santagostino, CEO & President, AGC Biologics | Onyx Live | Cell & Gene Meeting on the Med 2026
That bottleneck has become one of the biggest constraints on the next decade of cell and gene therapy growth, with hundreds of late-stage programs chasing a manufacturing footprint that has not expanded fast enough to match them.
Ali Soleymannezhad, Chief Commercial Officer, Cellares | Onyx Live | Cell & Gene Meeting on the Med 2026
An estimated 450,000 cancer patients were eligible for CAR-T in 2019; that number is projected to hit 2 million by 2029.